|
|
|
In this study, reported in Gene Therapy (Vol. 13, pp. 1587–1594, 2006), and published online on 06 July 2006, the authors (Gao et al.) developed a cell-specific cytotoxic model for the treatment of human pancreatic cancer (HPC) in which expression of antisense Smo (SAS) was under the control of the PTCH1 promoter (ptch/p) delivered by an adenoviral vector (Ad-ptch/p-SAS). Their study suggests that targeting at the Hh signaling pathway may be an effective novel gene therapeutic strategy alone or in combination with other agents for the treatment of pancreatic cancer.
Correspondence: Professor Z Li, Department of Gastroenterology, Changhai Hospital, Second Military Medical University, 174 Chang-Hai Road, Shanghai 200433, China.
E-mail: lizhaoshen111@yahoo.com.cn Abstract available online. (C) Gene Therapy. Posted by: Tressie Dalaya
Message posted by: Trevor M. D'Souza
|
|
Variants Associated with Pediatric Allergic Disorder
Mutations in PHF6 Found in T-Cell Leukemia
Genetic Risk Variant for Urinary Bladder Cancer
Antibody Has Therapeutic Effect on Mice with ALS
Regulating P53 Activity in Cancer Cells
Anti-RNA Therapy Counters Breast Cancer Spread
Mitochondrial DNA Diversity
The Power of RNA Sequencing
‘Pro-Ageing' Therapy for Cancer?
Niche Genetics Influence Leukaemia
Molecular Biology: Clinical Promise for RNA Interference
Chemoprevention Cocktail for Colon Cancer
more news ...
|